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Introduction 
 
Obesity is a serious and increasing threat to the health of populations 
globally. The high burden of obesity-related co-morbidities, such as 
type 2 diabetes (T2D), cardiovascular disease and certain cancers, 
heighten the severity of this obesity crisis. Globally, in 2008 over 200 
million men and almost 300 million women were obese, defined by 
body mass index (BMI ≥ 30 kg/m2), which represents an approximate 
doubling of the prevalence of obesity since 1980 [1]. Alarmingly, the 
prevalence of severe obesity (BMI ≥ 35 kg/m2) continue to rise 
rapidly in westernised societies [2,3,4], despite a flattening in the 
trend for levels of overall obesity [5]. Given the disproportionately 
higher health burden and healthcare costs associated with severe 
obesity [6], understanding the underlying mechanisms, including 
genetic factors, is a biomedical research priority.  
 
It is an inescapable fact that the underlying cause of obesity is a 
result of an individual consuming more energy than they expend. The 
rapid changes in lifestyle and food availability over the past 30 years 
have undeniably driven this rise in obesity. The question that is more 
complex to answer, however, is why some people eat more than 
others. Individuals respond differently to these ‘obesigenic’ 
environmental changes and it is increasingly clear that this variation 
in response has a very potent genetic element. BMI is heavily 
dependent on genetic susceptibility and studies of BMI correlations of 
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monozygotic, dizygotic, biological and adopted siblings have 
revealed the heritability of fat mass to be between 30% and 70%. 
These findings suggest that genetic factors play a significant role in 
the causes of individual differences in relative body weight and 
human adiposity [7]. Consequently, genetic approaches offer a 
powerful tool for characterising the molecular and physiological 
mechanisms of body weight control and allow us to understand how 
these may become ineffective in the obese state. Over the past 15 
years, insights from human and mouse genetics have illuminated 
multiple pathways within the brain that play a key role in the control of 
food intake. We now know for example, that the hypothalamic leptin–
melanocortin signalling pathway is central to the control of 
mammalian food intake, with genetic disruption of most components 
of the pathway resulting in severe obesity in both mouse and man [8]. 
The cloning and initial detection of mutations in the mouse and 
human leptin gene marked the beginning of the large-scale 
elucidation of DNA variation underlying inter-individual differences in 
body weight. Currently, several types of monogenic forms of obesity 
have been identified. All of these mutations are rare, some have only 
been reported in single cases worldwide; the respective genes are all 
expressed in the hypothalamus. The identification of such mutations 
and the successful treatment of leptin-deficient extremely obese 
individuals has firmly established that the behavioural phenotype 
hyperphagia/overeating and, as a consequence, obesity can be 
caused by mutations in specific genes [9,10]. These findings have 
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provided further support to the notion that obese individuals are 
responsible for their excess body weight to a limited extent only. 
Whereas the elucidation of each one of these monogenic forms of 
obesity has proven invaluable with respect to the insight into 
hypothalamic pathways involved in body weight regulation, the 
clinical implications of each of these findings are limited, because of 
the rare occurrence of these mutations. For instance, only a couple of 
research groups worldwide have reported on patients with 
functionally relevant mutations in the leptin or leptin receptor gene. 
For most of the monogenic forms of obesity, only single pedigrees 
with an affected individual have been reported [9,10]. Furthermore, 
several of the detected novel monogenic forms of obesity actually do 
not entail idiopathic obesity; instead the mutations can be viewed as 
giving rise to specific syndromes, which apart from obesity also 
encompass other clinically recognizable features. For instance, 
mutations in both the leptin and leptin receptor genes causel 
hypothalamic hypogonadism; other endocrinological abnormalities 
and immune system dysfunction have also been associated with 
leptin deficiency. In the original report of the clinical features of 
patients with mutations in the pro-opiomelanocortin gene (POMC), 
adrenal insufficiency and red hair were characteristic features in 
addition to extreme obesity [9,10]. The detection of mutations in the 
melanocortin-4 receptor gene (MC4R) marked a turning point in the 
sense that for the first time the molecular basis of a subgroup of 
patients with idiopathic obesity was identified. Whereas 
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hyperinsulinaemia and an elevated height growth have been reported 
as additional features of carriers of MC4R mutations the respective 
phenotype does not qualify as a readily distinct and clinically 
recognizable syndrome. The detection of the association between 
MC4R mutations and obesity is also noteworthy because the 
combined frequency of all functionally relevant mutations is in the 
range of 1–6% among extremely obese children and adolescents. 
MC4R mutations thus represent the first genetic form of obesity that 
affects a sizeable proportion of the obese population [9,10]. It is 
debatable if the term ‘monogenic obesity’ should be used in the 
context of MC4R mutations. Whereas there is little doubt that the rare 
occurrence of homozygosity or compound heterozygosity for 
functionally relevant mutations entails extreme obesity, the effect 
sizes of mutations in heterozygous carriers warrant discussion. For 
one, the body weights of heterozygous knockout mice are elevated, 
but overlap with those of wild-type mice. Furthermore, work in 
humans early on indicated that functionally relevant mutations also 
occur in normal-weight or lean controls. Approximately 130 mutations 
have been detected in the human MC4R gene; those leading to a 
reduced function entail a substantially elevated risk for the 
development of obesity. The coding variants in the MC4R that lead to 
a reduced receptor function seemingly support the ‘common disease 
– rare variant’ hypothesis, according to which a substantial proportion 
of the predisposition to complex disorders is due to rare variants. 
Indeed, it seems likely that other such loci exist in the genome that 
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cannot readily be picked up via linkage or association analyses due 
to locus heterogeneity and the low overall combined rate of such 
mutations at a specific gene locus. However, these and other 
monogenic syndromes of severe obesity remain very rare, with the 
major burden of disease carried by those with ‘‘common obesity’’ 
[9,10]. The first studies that searched for genes that predispose to 
common obesity were based on candidate genes, where the focus is 
on genes with a suspected role in the regulation of metabolism and 
food intake. Genetic variation in such candidate genes was 
subsequently examined for association with obesity and related traits 
in the general population. However, the candidate gene approach 
has suffered from some limitations, most notably the fact that many 
studies have been small and few results have been replicated. 
Furthermore, the selection of appropriate candidate genes requires a 
good understanding of the underlying biology and for many of the 
proposed candidate genes these pathways are still not fully 
understood. With progress in high-throughput genotyping and the 
availability of data from the Human Genome Project, genome-wide 
linkage studies provided an alternative methodology to search for 
obesity susceptibility genes. In genome-wide linkage studies, the 
whole genome of related individuals is screened for linkage of 
chromosomal regions with obesity or a related trait. Unlike candidate 
gene studies, which is hypothesis driven, genome-wide linkage 
studies do not rely on an a priori hypothesis but hope to identify 
previously unknown genetic loci, which may lead to new insights in 
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the biology. However, genome-wide linkage analyses have not been 
a powerful method for finding genetic loci with small effects as 
expected for common obesity. Similar to candidate gene studies, 
genome-wide linkage studies have suffered from lack of replication of 
results, mostly because many have small sample sizes [11]. There 
are an estimated 15 million sites along our genomes where one base 
can differ from one person or population to the next. By mid-2007, 
many of these locations, known as single-nucleotide polymorphisms 
(SNPs), had been charted. Subsequently, the HapMap, a catalog of 
SNPs was generated and used to track down genes involved in 
complex diseases so-called “genome-wide association studies” 
(GWAS). The GWAS approach is a high-throughput methodology 
that allows geneticists to scan a dense set of SNP (0.1–5 million 
SNPs) spanning across the entire human genome in an unbiased 
manner, using powerful statistical methods to study associations 
between a given disease phenotype and a representation of all 
common variation in the genome. The SNPs that show the highest 
level of association with the phenotype are taken forward into the 
follow-up stage of the study. The SNPs taken forward are tested for 
association in a new population, ideally one of at least similar size 
and design. The association results from the discovery and follow-up 
stages are meta-analysed. Since a very large number of association 
tests are performed in the discovery stage, there is a high likelihood 
of false-positive findings. Therefore, the significance levels used are 
very stringent. GWAS will in general only consider associations that 
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reach a value of p<0.5 x 10–8 as significant [10]. These SNPs are by 
no means considered causal; rather they operate as tag-SNPs that 
capture the common haplotypic variation in a given region of the 
human genome. If a given tag-SNP is associated with a particular 
trait, it signifies a region of typically a few hundred kilobases where a 
causative variant should reside. The success of the GWAS approach 
was made possible by the development of high-density genotyping 
arrays, which allow one to score the alleles for a large number of 
SNPs in parallel across the genome [10,12]. So, over the past 15 
years, the major focus has shifted from the detection of monogenic 
forms and major gene effects to the identification of common SNPs 
with substantially smaller effect sizes that explain inter-individual BMI 
variation at the population level. The results of GWASs underscore 
that the ‘common disease – common variant’ hypothesis is potentially 
also important [9,10]. This hypothesis states that specific common 
alleles or variants predispose to common disorders and that such 
alleles/variants will be found in all human populations. Indeed, for 
several complex traits and disorders common variants, mostly SNPs, 
have been detected in and outside of the coding and regulatory 
sequences of genes. It is mostly unclear how the detected variation 
alters the function of a gene. It appears likely that frequently, the 
respective SNP in itself merely tags a functionally relevant SNP, 
haplotype or variant (linkage disequilibrium). In addition, because 
such SNPs can be located far from a gene it is potentially not 
possible to definitely determine which gene is altered in its function. It 
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appears very likely that many of such functional variants influence 
gene expression levels. Similar to genome-wide linkage studies, 
GWAS are hypothesis generating and aim to identify new loci to 
increase our understanding of the biology that underlies the 
susceptibility to obesity. Three factors clearly differentiate obesity 
association studies in the pre and post GWAS era [9]:  
 
 A switch from the candidate gene approach to whole-genome 
studies was the result of the advent of DNA chip technology, 
which based on findings for several complex disorders can be 
viewed as a quantum leap forward in the elucidation of the 
genetic mechanisms underlying complex disorders. 
 
 In parallel, but not directly related to the introduction of DNA chip 
technology, the number of cases and controls used in association 
studies increased substantially; both the overall predominance of 
negative findings and the frequent failure to replicate associations 
based on candidate gene studies had been discussed as 
potentially reflecting a too low power. The transition to large-scale 
studies encompassing thousands of cases and controls (and 
meta-analyses) was boosted by the early results of GWAS which 
convincingly demonstrated that effect sizes are indeed small.  
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 Finally, population-based studies have entered the scene; the 
most recent GWAS meta-analysis emerged from both population-
based and case-control samples.  
 
In the pre-GWAS era, the MC4R was the first gene shown to 
unambiguously harbour a common variant with a small effect size; 
the original report already included a meta-analysis of all 12 case-
control studies that had been published at that time. The association 
of the minor allele, coding for Ile103, with leanness was confirmed in 
subsequent larger meta-analyses with up to almost 124,000 
probands. Roughly 3–6% of different populations are heterozygous 
for this variant, which according to a population-based data entails a 
0.5-kg/m2 reduction in mean BMI. This would qualify this SNP as the 
one with the strongest effect size of all currently known common 
variants. More recently, GWAS meta-analyses localized SNPs more 
than 150 kb downstream of the MC4R, which also account for inter-
individual BMI variation. The MC4R is thus currently unique in that it 
harbours variants of considerably different effect sizes both within 
and outside the coding region and whose minor alleles both increase 
and decrease BMI [9,10]. To date, in the quest to elucidate the 
biological basis of obesity, GWAS have identified more than 40 
genetic variants that are associated with BMI or risk for obesity [13-
15]. Previous GWAS reports for severe adult obesity case-control 
samples identified associations only with SNPs within the intronic 
FTO (Fat mass and Obesity related transcript) locus [16,17], 
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consistent with the robust association of these SNPs with increased 
BMI and adiposity across different ages and populations. Although 
the discovery with GWAS of other ‘polygenic’ obesity loci, FTO still 
remains the gene with the most robust association and greatest 
effect size [14]. In 2007, a T2D GWAS identified SNPs in the first 
intron of FTO associated with disease. However the association 
between these FTO SNPs and T2D disappeared after adjustment for 
BMI. With increased weight being a risk factor for T2D, it suggested 
that these SNPs are actually associated with BMI [18]. FTO is an 
AlkB-like 2-oxoglutarate-dependent nucleic acid demethylase of 
uncertain cellular function [19]. Subjects homozygous for the obesity-
risk (A) allele of FTO rs9939609 have a 1.7-fold increased risk for 
obesity compared to subjects homozygous for the low-risk (T) allele 
[20-25]. Evidence to date suggests that the association between 
SNPs in FTO and BMI is predominantly driven by increased energy 
intake. Subjects homozygous for the A ‘obesity-risk’ allele of 
rs9939609 exhibit overall increased ad libitum food-intake [26-28], 
particularly fat consumption [25,27-29], and impaired satiety [30,31]. 
Furthermore, pre-school AA children exhibit obesity-prone eating 
behaviours, including increased food responsiveness and tendency 
to eat in response to external cues, prior to the development of an 
association between FTO rs9939609 and BMI [32]. FTO rs9939609 
also has per-allele effects on feeding behavior [28] and BMI [20]. 
Several lines of evidence from rodent studies are consistent with 
FTO playing a key role in regulating energy homeostasis. Firstly, 
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FTO is highly expressed in brain regions controlling feeding and 
energy expenditure, such as the hypothalamus [20,33]. Secondly, 
hypothalamic FTO expression is modulated by fasting [20,34-38], 
and restricted access to food [40] although both up-regulation [35-36] 
and down-regulation [19,36,37] have been reported, apparently 
depending on the severity of caloric restriction. Exposure to high-fat 
diet also modulates hypothalamic FTO expression, with down-
regulation reported with short-term exposure [38] and up-regulation 
with more prolonged exposure [40]. Further evidence suggesting that 
FTO is nutritionally regulated comes from in vitro studies in mouse 
and human cell lines where glucose and total amino acid deprivation 
decreases FTO expression [41,42]. Finally, phenotypic analyses of 
transgenic mice in which FTO function is either eliminated or 
enhanced, further implicate a role of FTO in regulating energy 
homeostasis. Mice with constitutive FTO deletion exhibit a tendency 
for leanness [43-45] and similarly mice generated with a dominant 
missense mutation in the C-terminal of FTO, leading to a partial loss-
of-function, also display a lean phenotype [46]. In contrast, mice with 
global FTO overexpression have increased food intake, body weight 
and fat mass [47]. However, despite the compelling genetic evidence 
that SNPs in FTO are associated with increased BMI and the recent 
advances in our understanding of the targets of FTO, the 
mechanisms by which FTO SNPs lead to obesity-prone eating 
behaviour and obesity remain unknown. A recent study conducted by 
Batterham and colleagues in a group of adiposity-matched normal-
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weight humans, showed that subjects homozygous for the FTO 
‘obesity-risk’ rs9939609 A-allele have dysregulated circulating levels 
of the orexigenic hormone acyl-ghrelin and attenuated post-prandial 
appetite reduction. Then using functional MRI (fMRI) in normal-
weight AA and TT humans, they showed that FTO genotype 
modulates the neural responses to food images in homeostatic and 
reward brain regions. Furthermore, AA and TT subjects exhibit 
divergent neural responsiveness to circulating acyl-ghrelin within 
brain regions that regulate appetite, reward-processing and incentive 
motivation. Their findings showed that FTO regulates ghrelin, a key 
mediator of ingestive behaviour, and offers new insights into how 
FTO obesity risk-alleles predispose to increased energy intake and 
obesity in humans [48]. Because many of the 32 SNPs-detected 
genes are expressed in the central nervous system, the role of the 
brain in the regulation of body weight is seemingly substantiated. 
However, the high proportion of all genes (≈80% in mouse brain) 
expressed centrally needs to be considered prior to drawing firm 
conclusions. Pathway-based analyses, depending on the genes 
identified via the association signals, revealed evidence of 
enrichment for pathways involved in the platelet-derived growth factor 
signalling, translation elongation, hormone or nuclear hormone 
receptor binding, homeobox transcription, regulation of cellular 
metabolism, neurogenesis and neuron differentiation, protein 
phosphorylation and numerous other pathways related to growth, 
metabolism, immune and neuronal processes [9]. Despite the 
15 
 
identification of many obesity-related loci, yet very little of the 
apparent heritability has been explained. Only a low percentage of 
the estimated heritability has been explained for most complex traits 
when applying GWAS; indeed, the strongest obesity-associated 
variants in FTO and MC4R only account for less than 2% of the 
variance in adult BMI, with the combined results of all obesity GWAS 
loci still accounting for only a very small fraction of the heritability of 
BMI. As such, there is a great deal of debate on what the missing 
heritability of most complex traits consists of. The main hypothesis 
right now is that it is made up of much rarer variants, copy number 
variants and epigenetic changes that are not detected within the 
bandwidth of GWAS. There is, of course, the counter argument that 
the estimates of missing heritability are incorrect. Authors suggested 
that the estimated missing heritability not picked up by GWAS could 
be hugely overinflated, as the assumption is that the genetic variants 
uncovered to date do not interact with each other. Even if they 
interact modestly, then missing heritability estimates could be 
somewhat different from current understanding. Despite these great 
advances, the combined results of linkage, candidate gene, and 
GWAS approaches have explained very little of the variance in BMI, 
suggesting that there are still many genetic findings to be made, most 
likely being rarer variants exhibiting small effects [10]. The FTO locus 
has the largest effect size of the 32 established BMI-associated loci; 
for each additional risk allele, BMI increases by 0.39 km/m2 
(equivalent to an increase of 1.1 kg for someone 170 cm tall). It also 
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has a comparatively high effect allele frequency of 42%. The 
discovery of the locus near MC4R required a much larger sample 
size, not only because its risk allele frequency is lower, but also 
because its effect size is smaller than that observed for the FTO 
locus. For each additional risk allele at the near-MC4R locus, BMI 
increases by 0.23 kg/m2 (or 0.6 kg). The effects of the subsequently 
indentified loci range from 0.06 to 0.33 kg/m2 (or 0.2 to 1.0 kg). In 
general, the effect sizes of the loci observed in the more recent and 
bigger studies tended to be smaller. Despite strong evidence of 
association for each of the 32 loci, combined they explain only a 
fraction of the total variation in BMI (1.45%) [11]. In order to fully 
characterize this missing heritability, larger and larger sample sizes 
are going to be required to improve statistical power. New 
technologies, such as next generation sequencing, will help us 
identify these elusive obesity-associated variants, particularly as the 
price of these techniques continues to drop [9,10].  Previous studies 
have suggested that individuals who have extreme obese 
phenotypes, such as early onset (BMI ≥ 95th percentile achieved 
before the age of 10-18 years old) [49,50] or severe adult obesity 
[16], represent an extreme tail of the population BMI variation, with a 
higher burden of shared genetic factors [51].  Alternatively, extreme 
obesity may be viewed as a separate entity with distinct underlying 
genetic factors [14]. In contrast, other GWAS evaluating early onset 
extreme obesity detected loci distinct from those identified in the 
meta-analysis of adult BMI [52-54]. Importantly, a recent genome-
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wide analysis for loci associated with clinical classes of obesity and 
extreme BMI tails [15], drawn from populations within the prior 
Genetic Investigation of ANthropometric Traits (GIANT) meta-
analysis of adult BMI, detected no new loci associated with class 3 
obesity (BMI ≥ 40 kg/m2), in addition to those uncovered in the 
original meta-analysis. While two new loci were found to be 
associated with class 2 obesity (BMI 35.0-39.9 kg/m2), this study 
provides strong evidence that the majority of common BMI-increasing 
variants continue to have effects across the full BMI spectrum. 
 
Bariatric or weight-loss surgery is indicated for patients with a BMI ≥ 
40.0 kg/m2 or ≥ 35.0 kg/m2 in the presence of at least one obesity-
related comorbidity, and currently represents the most effective 
treatment for patients with severe obesity [55]. In light of the marked 
health benefits of bariatric surgery, the number of patients being 
referred for bariatric surgery assessment is increasing, with over 
340,000 bariatric procedures undertaken in 2011 [56]. The 
assessment of patients in bariatric surgery centres thus offers an 
opportunity to undertake genetic studies in a population at the upper 
tail of the BMI spectrum.  
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Aim of the Study: 
We investigated whether 32 known common obesity-susceptibility 
variants are enriched in a cohort of patients with severe obesity 
attending a bariatric surgical assessment clinic, compared with 
normal-weight (BMI 18.0-24.9 kg/m2) controls and if a combination of 
these SNPs in a genetic risk score is associated with severe obesity. 
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Methods 
Study population and anthropometric measures 
 
Patients were recruited from two bariatric centres; the University 
College London Hospitals (UCLH) Centre for Weight-loss, Metabolic 
and Endocrine Surgery, London, UK and the University Hospital of 
Pisa (UHP), Pisa, Italy. Individuals of European descent were 
included in the analyses in order to facilitate comparison with a UK 
population-based control group. Patients with a BMI ≥ 35.0 kg/m2 
who donated a peripheral blood sample for DNA analysis were 
recruited to the study. At the UCLH Centre, 585 patients who 
attended bariatric surgery clinics were recruited between October 
2009 and October 2012. Of these 585 patients, 26 were excluded 
due to incomplete clinical data (n = 11), absence of genotyping (n = 
6), unsuccessful genotyping (n = 4) or a documented BMI of <35.0 
kg/m2 (n = 5), which resulted in a total of 559 patients from the UCLH 
centre being included. 36 UCLH patients, who had undergone 
previous bariatric surgery for treatment of severe obesity (BMI ≥ 35.0 
kg/m2) at other bariatric centres, were included in the case-control 
analysis but not in the analysis for SNP effects on BMI. 444 Italian 
patients who attended to the Obesity Centre at the Endocrinology 
Unit of the University Hospital of Pisa, Italy, from January 2003 to 
December 2011, for evaluation prior to bariatric surgery, were 
recruited to the study. Thus, 1,003 samples were available for the 
20 
 
case-control analysis and 967 (excluding n = 36 patients who had 
previous bariatric surgery) were included in the within-group analysis. 
BMI was calculated from the weight and height measurements 
recorded at the first visit to the bariatric clinic. Weight was measured 
using the Walkthrough Platform A12SS Stainless Steel Indicator. 
Height was measured using a wall-mounted digital stadiometer. 
Demographic and comorbidity data were collected by means of an 
electronic clinical data record. The National Health Service Research 
Ethics Committee approved the research protocol and all participants 
provided written informed consent. The control group was comprised 
of normal-weight population-based controls from the British 1958 
Birth Cohort (B58C) who were previously genotyped either as part of 
the Wellcome Trust Case Control Consortium 2 [57] or another 
related genotyping effort [58]. From a total of 5,382 B58C reference 
samples, we selected individuals with BMI in the normal range (18.0-
24.9 kg/m2, mean 22.8±1.6 kg/m2), amounting to 1,809 normal-
weight controls, 64% of whom were female and 36% male. B58C 
controls had anthropometric data measured during a biomedical 
examination undertaken at the age of 44-45 years [59].  
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DNA extraction and quantification of bariatric surgery 
case samples 
 
All DNA extractions from peripheral blood samples were performed 
using the QIAamp DNA Blood Midi Kit (Qiagen) according to the 
manufacturer's instructions. DNA concentration and purity were 
determined with UV spectrophotometry (Nanodrop) measuring the 
spectrophotometric absorbance ratios of 260nm/280nm. High quality 
DNA was considered to have an A260/A280 ratio of 1.85 - 2.10. All 
genomic DNA was diluted to a final concentration of 5 ng/l. 
 
SNP genotyping of bariatric surgery case samples 
 
30 single nucleotide polymorphisms (SNPs) corresponding to loci 
identified in the GIANT meta-analysis of adult BMI [14] were 
genotyped (Table 2). Genotyping was not successful for two other 
SNPs, rs12444979 near GPRC5B and rs4836133 near ZNF608. Two 
further SNPs, corresponding to the additional loci near HOXB5 and 
OLFM4 uncovered in a meta-analysis of childhood severe obesity 
[49] and which also yielded directionally consistent associations in 
the meta-analysis of adult BMI [14], were also genotyped. Of note, 
the FTO SNP genotyped was rs9939609, which was the SNP 
reported in the first GIANT GWAS [13] and is in strong to complete 
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linkage disequilibrium with other reported intronic FTO SNPs [60]. 
Genotyping of bariatric patients was performed by KBioscience 
(Hertfordshire, UK). SNPs were genotyped using the KASP 
(KBioscience Competitive Allele-Specific PCR) SNP genotyping 
system). The following quality criteria were applied to both bariatric 
cases and B58C control samples: HWE p-value > 0.0001, genotype 
callrate > 95%, and sample callrate > 90%. Blind duplicates were 
used to detect possible DNA mixup. 
 
Statistical analysis 
 
Statistical analyses were performed using the programs PLINK [61], 
SNPTEST [62], and R software environment [63]. Logistic regression 
analyses were performed using an additive genetic model to evaluate 
the difference between the normal-weight control group (n = 1,809) 
and the sample of bariatric surgery patients (n = 1,003). Additionally, 
linear regression analyses with an additive genetic model were 
performed for BMI within the bariatric sample-set alone (n = 967, 
excluding n = 36 patients who had previous bariatric surgery), firstly 
using standardized BMI values in order to compare effect sizes within 
the bariatric cohort with the known effect sizes derived from inverse 
standardized BMI values in the published meta-analysis [14], and 
secondly, using unstandardized BMI values in considering the BMI 
distribution of the bariatric cohort sample-set. To compare between 
the reference effect sizes from the published meta-analysis [14] and 
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effect sizes in the bariatric cohort, we used a standard t-test. 
Secondary logistic and linear regression analyses were performed 
using both dominant and recessive models. Power analysis for single 
marker effects, performed with a genetic power calculator taking a 
trait prevalence of 4%, a risk allele frequency of 20%, and p-value 
threshold adjusted for 32 independent samples (α = 0.05/32 = 
0.00132), showed that power estimates for genotype relative risks of 
1.1, 1.15, 1.2 and 1.25 were 4.2%, 15.1%, 36.9% and 62.9% 
respectively. All analyses were adjusted for gender, age and country 
of origin. A previous analysis demonstrated that the common BMI-
increasing SNPs do not appear to have strong allele frequency 
differences across five diverse European populations, including the 
B58C cohort and an Italian cohort [14], therefore a specific Italian 
control sample-set was not sought. Multiple marker analyses were 
performed with PLINK [61] using genetic scores calculated from all 
32 genotyped markers with their relative weight based on their effect 
sizes in the published meta-analysis [14]. Linear regression model in 
R was used for evaluating the predictive value of the genetic score in 
relation to BMI within the bariatric cohort and logistic regression was 
used to determine the extent to which genetic scores distinguished 
between the normal-weight control and bariatric cohort groups.  
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Results 
 
A total of 1,003 patients attending a bariatric surgery assessment 
clinic were included in the case-control analyses (see Table 1 for 
baseline demographic and anthropometric characteristics). Firstly, we 
undertook a comparison of the effects of BMI-raising SNPs in the 
normal-weight control (n = 1,809) and the bariatric surgery (n = 
1,003) groups to determine whether known BMI-increasing SNPs are 
associated with severe obesity in our cohort. We found associations 
for SNP rs9939609 within the FTO gene (P = 9.3 x 10-8) and SNP 
rs2815752 near the NEGR1 gene (P = 3.6 x 10-4). Directionally 
consistent nominal associations were also detected for SNPs at 
the FAIM2, TMEM18, PRKD1, SLC39A8 and MC4R(B) loci (P < 
0.01), and at the TNNI3K, OLFM4, LRP1B, KCTD15, TFAP2B, 
GNPDA2 and SEC16B loci (P <0.05) (Table 2). Analysis of SNPs at 
the other 18 loci did not reveal any evidence of association. However, 
9 of these 18 SNPs had effects directionally consistent with the 
GIANT meta-analysis results (Table 2). Secondary analyses using 
both dominant and recessive models revealed similar results to the 
additive model. Stronger associations were found for six SNPs using 
the dominant model and for two SNPs using the recessive model. 
Upon combining all 32 genotyped SNPs into a genetic risk score, we 
found a significant difference in the average risk score between 
normal-weight control group and the bariatric surgery group (P = 8.3 
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x 10-11, adjusted R2 = 0.0043) (Figure 1). Comparison of the effects of 
BMI-associated SNPs in patients in specific BMI categories in the 
bariatric cohort (< 40.0 kg/m2, 40.0-44.9 kg/m2, 45.0-49.9 kg/m2, 
50.0-59.9 kg/m2, ≥ 60.0 kg/m2) and the normal-weight control group 
revealed that both the strongest effects for the SNP rs9939609 within 
the FTO gene (β = 1.08  ± 0.23, P = 3.4 x 10-6) and the weakest 
effects for the SNP rs2815752 near the NEGR1 gene (β = 0.02  ± 
0.22, P = 0.9) were in the ≥ 60.0 kg/m2 BMI category (Table 3). In 
order to place our findings in the context of the recent GIANT-
extremes results [15], we compared the effects of the BMI-increasing 
SNPs on odds of severe obesity in our study with those from the 
GIANT-extremes analyses and detected no significant differences 
(Figure 2). 
 
Next, we examined the association of the BMI-increasing SNPs with 
BMI within the bariatric surgery cohort alone (n = 967, excluding n = 
36 patients who had previous bariatric surgery). Nominal 
associations with BMI were found only for SNP rs9939609 within the 
FTO gene (P = 0.01, β = 0.11 ± 0.04) and with SNP rs2815752 near 
the NEGR1 gene, however, paradoxically, there was a negative 
effect direction for the NEGR1 locus effect allele (P = 0.03, β = -0.1 ± 
0.05). Furthermore, the 32 SNP genetic risk score did not distinguish 
between BMI values within bariatric surgery patients (P = 0.264, 
adjusted R2 = 0.0045). We then undertook linear analyses, using both 
standardized and unstandardized BMI values, to compare the effects 
26 
 
on BMI within the bariatric surgery group with previously published 
data from the GIANT meta-analysis of adult BMI (GIANT-BMI) [49]. 
These analyses revealed no significant differences between the 
compared effect sizes (Figure 3A-B).  
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Discussion 
 
In a comparison with normal-weight controls, our analysis of 
genotype data from European adults with severe obesity attending 
two bariatric surgery centres has again demonstrated a strong 
association of the intronic FTO SNP rs9939609 with severe obesity. 
Furthermore, we have shown that a further 13 of the other 31 obesity 
susceptibility loci that we investigated are at least nominally 
associated with severe obesity in this cohort of patients being 
assessed for bariatric surgery. Combination of the 32 SNPs into a 
genetic risk score convincingly distinguished between normal BMI 
controls and severely obese patients, which further highlights the 
influence of common variants on the presence of severe obesity in 
adults. Our study is, to our knowledge, the first to perform such a 
comprehensive polygene risk score in a cohort of patients with 
severe obesity specifically in the setting of a bariatric surgery clinic, 
ranging from complicated class 2 obesity (BMI 35.0-39.9 kg/m2 in the 
presence of at least one obesity-related comorbidity) to the super 
super-obese category (BMI ≥60.0 kg/m2) (Table 3). Our results 
suggest that severe obesity represents an extreme of the continuum 
of BMI variance in the general population, consistent with the results 
from the recent GIANT-extremes analysis [15]. 
 
The methodological approach relating to the polygene risk score 
represents a novel aspect of our study. While one previous case-
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control GWAS also specifically studied subjects with severe obesity 
(mean BMI 50.4±8.1 kg/m2), who were attending a bariatric surgery 
centre, there are important differences between our study design and 
that of the Cotsapas et al. study [16]. After finding a genome-wide 
association with severe obesity for the FTO locus, the investigators 
then evaluated 12 of the known BMI-associated loci for association 
with severe obesity. They found that there was a higher burden of 
risk alleles in patients with severe obesity than in controls and in the 
more extreme half of BMI distribution within this bariatric cohort [16]. 
In contrast, we employed a more comprehensive analysis evaluating 
the contribution of 32 common BMI-increasing SNPs to severe 
obesity. Rather than using the approach of comparing number of risk 
alleles as in the Cotsapas et al. study, the genetic scores in our study 
were calculated based on the relative weight of the SNP effect sizes 
reported in GIANT-BMI meta-analysis. Furthermore, our study 
employed a comparison with normal-weight controls, whereas the 
anthropometric data of the controls in the Cotsapas et al. study were 
not available. Previous studies have used such risk scores in the 
setting of extremes of obesity, with varying results, however these 
studies employed a more limited panel of SNPs [50,16,54,64]. 
Nevertheless, the polygenetic approach employed in the GIANT-
extremes analysis demonstrates the utility of combining multiple 
common variants, including those with effect size <0.05, in explaining 
BMI variance [15].  
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Our results are consistent with previous studies demonstrating that 
SNPs in the first intron of FTO bear the strongest association with 
obesity, of the known BMI-raising SNPs [14,16,17], and also are 
strongly associated with extremes of obesity [15,16,17,52,54,65,66]. 
We found that the FTO SNP rs9939609 was also nominally 
associated with BMI within the severe obese cohort. Furthermore, 
among the 32 loci, the FTO locus held the strongest association and 
largest effect size in patients with a BMI ≥ 60.0 kg/m2. Taken 
together, these findings suggest that FTO variants retain an 
important contributory role in the pathogenesis of obesity at 
increasing levels of severe obesity. The robust association of the 
FTO locus with severe obesity is likely to be mediated through well-
documented effects on increasing energy intake [67], and it is highly 
likely that the altered function in the FTO gene itself is 
mechanistically responsible for the phenotypic effects [68]. However, 
the mechanisms underlying the FTO risk allele phenotype and the 
SNP effects on FTO gene function remain to be fully explored. 
Interestingly, in this regard, recent evidence suggests that the 
functional effects of the FTO SNP rs9939609 may be mediated 
through differential methylation of FTO itself [69] and myriad other 
genes [70]. 
 
Along with the strong association of the FTO locus, we also detected 
association of the SNP rs2815752 near the NEGR1 gene with severe 
obesity. This NEGR1 SNP ranked among the top four most strongly 
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associated with extremes of obesity of all 32 BMI-associated loci in 
the GIANT analyses [14,15]. Interestingly, we found that the NEGR1 
risk allele had a negative effect direction in relation to BMI within the 
bariatric cohort, a finding that reached nominal significance and in 
keeping with the consistent decreasing trend in effect size with 
increasing BMI categories observed (Table 3). Notably, a recent 
GWAS analysis demonstrated an association of two deletions (43kb 
and 8kb) upstream of NEGR1 with early onset extreme obesity [54]. 
Importantly, these deletions segregate on distinct haplotypes [12]. 
The rs2815752 SNP is known to tag the 43kb deletion [12], however 
the protective 8kb deletion is the major driver of the association with 
extreme obesity at the NEGR1 locus and is tagged by an alternative 
SNP (rs1993709) [54]. In this context, our findings suggest that the 
NEGR1 rs2815752 SNP contributes to the genetic risk of severe 
adult obesity, likely driven by the alternative signal [54], but that the 
effects may be predominantly relevant at lower points on the 
continuum of severe adult obesity. The comparable effects observed 
in our study and data from Wheeler et al. [54] highlights the important 
contribution of the NEGR1 locus to both adult and early onset forms 
of severe obesity. However, further studies with increased power are 
required to confirm our finding that, contrary to the early onset form 
[54], there is a relatively smaller contribution of the NEGR1 locus at 
the extreme tail of the severe adult obesity spectrum. Of note, 
NEGR1 has been implicated in hypothalamic control of body weight 
and food intake [71]. Evidence for a possible functional basis for the 
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association effects of variants at the NEGR1 locus have also been 
explored [54]. Evidence that the 8-kb deletion upstream of NEGR1 
encompasses a single binding site for a transcriptional repressor of 
NEGR1 begins to provide valuable insights into why these NEGR1 
variants are associated with severe obesity [54], however the 
downstream mechanisms underlying the association remain to be 
elucidated.  
The lower magnitudes of association with severe obesity found for 
the other 12 BMI-increasing SNPs suggest that these loci exert a 
smaller influence on the development of severe obesity. However, 
power issues relating to the sample size of our study are likely to 
have impacted upon the strength of the associations. Our finding that 
only 9 of the remaining 18 SNPs had effects directionally consistent 
with the GIANT-BMI results [14] raises the possibility that a 
proportion of SNPs that are associated with BMI in the general 
population may not contribute to severe obesity. This is in contrast 
with the data from the GIANT-extremes analysis, in which the effects 
of all 32 BMI-associated loci on all obesity-related traits were 
directionally consistent with the prior study of adult BMI, although 4 
SNPs were not at least nominally associated with class 3 obesity 
[15]. However, it is important to note that there is a considerable 
overlap between the populations used for GIANT-extremes [15] and 
the prior GIANT-BMI meta-analysis [14]. Our study was undertaken 
in an independent cohort of patients with severe obesity, and this 
methodological difference may account for our divergent findings. 
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There is also evidence from the recent study in the SCOOP cohort 
(UK children of European ancestry with severe early-onset obesity, n 
= 1,509) [54], that there is an incomplete overlap between loci 
influencing obesity-related phenotypes among the general adult 
population (GIANT) or early onset severe obesity (SCOOP). This 
concept is supported by comparing results from case-control studies 
of extreme obesity, including our findings, suggesting that extreme 
obesity is a heterogeneous disorder with varying genetic influences, 
both shared and unshared across the spectrum. Nevertheless, in our 
study, we did not find any significant differences between odds ratios 
or effect sizes when compared with GIANT-extremes data [15] 
(Figure 2) or GIANT-BMI data [14] (Figure 3A-B) respectively. 
Therefore, the relatively small sample sizes in the studies may have 
impacted upon the strength of the associations with common BMI-
associated variants detected, in particular for risk alleles with 
relatively lower frequencies such as the PRKD1 risk allele. 
Interestingly, the sample size in our study compares well with that of 
class 3 obesity in the GIANT-extremes study, drawn from a pool of 
over 260,000 individuals, highlighting the productive potential for 
undertaking genetic studies in patients attending bariatric centres.  
 
There are a number of potential limitations pertaining to our study, 
chief amongst them is the lack of a ‘hypothesis-free’ study design. 
Our results should be interpreted with caution, in this regard, as our 
research question may have introduced a bias into the findings. 
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Furthermore, our study did not address other genetic factors such as 
highly penetrant rare variants, that may exert an increasing 
contribution in more extreme obesity and therefore contribute to the 
‘missing heritability’ of BMI-related phenotypes [9]. For example, the 
recent genome-wide copy number variation (CNV) analysis again in 
the SCOOP cohort demonstrated a higher burden of rare, and in 
particular, singleton CNVs in the extreme obesity cohort compared to 
controls [54]. Furthermore, we acknowledge that our study is 
insufficiently powered to replicate findings for all BMI-associated loci, 
many of which were identified only using sample sizes several orders 
of magnitude higher than in our study [14]. However, the potential to 
replicate some of the strongest signals remained and we were also 
able to test if any known loci had stronger effects in such an extreme 
obesity dataset compared to the published population-based data. 
Our findings in relation to the modest effects of these specific 
common BMI-associated variants, as aptly demonstrated in Figure 1, 
are consistent with the well-documented gap between explained 
variance due to common variants (~2%) and estimated heritability 
(h2) of obesity (~40-70%) [9,10,72]. However, a novel approach 
called genome-wide complex trait analysis (GCTA) has yielded 
results that suggest there are a multitude of low penetrance common 
variants, each with causal effects too small to allow detection by 
GWAS, together accounting for up to 17% of the overall BMI variance 
[73], which has been further corroborated by the GIANT-extremes 
polygene analysis [15]. Such a GCTA approach has also been 
34 
 
undertaken in a recent analysis of twin studies and revealed that 37% 
of BMI h2 could be explained by the effects of multiple common SNPs 
[74]. An additional consideration is that the heritability of severe 
obesity is not as well delineated as for overweight and lower levels of 
obesity, although familial aggregation of severe obesity is well 
documented [72]. Many of the classical twin studies involve less 
obese populations and are not directly generalizable to severe 
obesity [7]. Gene-environment interactions are another potential 
explanation for the unexplained heritability [72]. In this light, while our 
results suggest that accumulation of common variants predisposes to 
severe obesity, actual BMI in adults with severe obesity may be 
relatively more dictated by other factors including environmental 
influences [75], compared to individuals in lower BMI categories. 
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Conclusion 
In summary, we have demonstrated that, among 32 BMI-increasing 
common variants, at least 2 are strongly associated and 12 other 
variants are nominally associated with severe obesity in patients 
attending a bariatric surgery centre. Combination of all 32 genotyped 
SNPs in a genetic risk score was associated with severe obesity, 
however the risk score was not associated with actual BMI within the 
bariatric cohort. We conclude that significant effects of individual 
BMI-associated common variants can be found even in a relatively 
small sample size, in a comparison of a bariatric cohort to normal-
weight controls, and that the burden of such low-penetrant risk alleles 
contributes to severe obesity in this population. These findings add 
more support to the hypothesis that severe obesity represents an 
extreme tail of the population BMI variation. However, the limitations 
of our study prevent us from drawing any conclusions regarding the 
relative importance of common genetic variants compared to other 
factors, genetic or otherwise, that are likely to contribute to severe 
obesity. Nevertheless, future genetic studies focused on bariatric 
patients may provide valuable insights into the pathogenesis of 
obesity at a population level.   
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Figures and Tables: 
 
Figure 1. Boxplot showing genetic risk scores in bariatric patients 
compared to normal-weight controls. The average genetic risk score 
differentiated well between normal-weight controls group and the bariatric 
surgery group (P = 8.3 x 10-11). 
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Figure 2. Comparison of the results of our logistic regression analysis 
versus GIANT-extremes results using combined data from obesity class 2 
and 3 groups [11]; odds ratio (OR) with 95% confidence intervals (CI). 
There were no significant differences between the compared OR. See 
Table 2 for allocated reference numbers of SNPs. The diagonal line 
represents the expected plotted values for our results, based on the GIANT-
extremes results. The SNPs below the diagonal line are those which had a 
larger effect in our study compared to GIANT-extremes, whereas the SNPs 
above the diagonal line represent SNPs which had a larger effect in GIANT-
extremes compared to our study 
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Figure 3. Comparison of effect sizes (i.e. changes in BMI) within the 
bariatric cohort, calculated by using standardized BMI values (A), with the 
known effect sizes derived from inverse standardized BMI values in the 
GIANT-BMI meta-analysis [10], and by using unstandardized BMI values 
(B). Of note, the FTO marker effect size plotted for the GIANT-BMI data 
relates to the SNP rs1558902 (SNP rs9939609 in our study).  
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Table 1. Baseline demographic and clinical characteristics of bariatric patients 
 
 
 
 
 
 
 
 
 All UCLH, London UHP, Pisa 
Total number (n) 
Excluded n = 
Included n = 
1,029 
26 
1,003 
585  
26 
559 (56) 
444  
0 
444 (44) 
    
Age* (years) 44.6±11 45.5±10.8 43.5±11.1 
Female (%) 
Male (%) 
709 (71) 
294 (29) 
370 (66) 
189 (34) 
339 (76) 
105 (24) 
 
BMI* (kg/m2) 48.4±8.1 48.7±7.9 48.2±8.3 
Type 2 diabetes (n, %) 260 (26) 157 (28) 104 (23) 
Metabolic risk** (n, %) 583 (58) 299 (53) 284 (64) 
Prev. bariatric surgery (n, %) 36 (4) 36 (6) 0 (0) 
 
*Data are shown as mean ± SD 
**Defined as presence of ≥1 major cardiovascular risk factor 
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Table 2. Results of logistic regression for the 32 genotyped SNPs 
#Ref Nearest  
gene 
Chr rsid Effect  
allele 
EAF  
cases 
EAF  
control 
β P OR 
#1 NEGR1  1 rs2815752 A 0.67 0.59 0.25 3.6x10-4 1.29 
#2 PTBP2 1 rs1555543 C 0.57 0.60 -0.12 0.08 0.88 
#3 SEC16B 1 rs543874 G 0.22 0.21 0.17 0.04 1.19 
#4 TNNI3K 1 rs1514175 A 0.45 0.41 0.18 0.01 1.19 
#5 FANCL 2 rs887912 T 0.32 0.29 0.13 0.09 1.14 
#6 LRP1B 2 rs2890652 C 0.16 0.14 0.23 0.02 1.26 
#7 RBJ 2 rs713586 C 0.48 0.49 -0.004 0.95 0.99 
#8 TMEM18 2 rs2867125 C 0.84 0.81 0.26 0.005 1.29 
#9 CADM2 3 rs13078807 G 0.22 0.19 0.14 0.11 1.15 
#10 ETV5 3 rs9816226 T 0.83 0.81 0.17 0.07 1.18 
#11 GNPDA2 4 rs10938397 G 0.45 0.41 0.16 0.02 1.17 
#12 SLC39A8 4 rs13107325 T 0.09 0.07 0.35 0.008 1.42 
#13 FLJ35779 5 rs2112347 T 0.62 0.63 -0.07 0.36 0.93 
#14  NUDT3 6 rs206936 G 0.23 0.19 0.07 0.44 1.07 
#15 TFAP2B 6 rs987237 G 0.20 0.17 0.22 0.02 1.24 
#16 LRRN6C 9 rs10968576 G 0.27 0.31 -0.003 0.97 0.99 
#17 BDNF 
(B,M) 
11 rs10767664 A 0.78 0.77 0.16 0.06 1.17 
#18 MTCH2  11 rs3817334 T 0.42 0.41 0.06 0.41 1.06 
#19 RPL27A 11 rs4929949 C 0.46 0.52 -0.06 0.36 0.94 
#20 FAIM2 12 rs7138803 A 0.40 0.36 0.21 0.004 1.23 
#21 MTIF3 13 rs4771122 G 0.23 0.22 0.09 0.27 1.10 
#22 OLFM4 13 rs9568856 A 0.14 0.12 0.25 0.02 1.28 
#23 NRXN3 14 rs10150332 C 0.21 0.21 0.16 0.06 1.18 
#24 PRKD1 14 rs11847697 T 0.06 0.04 0.44 0.007 1.55 
#25 MAP2K5 15 rs2241423 G 0.75 0.77 -0.05 0.56 0.95 
#26 FTO 16 rs9939609 A 0.49 0.38 0.38 9.2x10-8 1.47 
#27 SH2B1  16 rs7359397 T 0.33 0.39 -0.14 0.05 0.87 
#28 HOXB5 17 rs9299 T 0.64 0.66 -0.09 0.2 0.91 
#29 MC4R (B) 18 rs571312 A 0.27 0.22 0.22 0.007 1.24 
#30 KCTD15 19 rs29941 G 0.71 0.67 0.17 0.02 1.19 
#31 QPCTL 19 rs2287019 C 0.84 0.81 0.16 0.08 1.17 
#32 TMEM160
(Q) 
19 rs3810291 A 0.66 0.68 -0.12 0.12 0.89 
#Ref, reference number of SNPs allocated for Figures 2 and 3; Chr, chromosome; rsid, reference SNP 
identification number; Effect allele, BMI-increasing allele as reported in the GIANT-BMI meta-analysis; 
EAF, effect allele frequency; β; effect size; OR, odds ratio. 
SNPs yielding at least nominal evidence for association are highlighted in bold and SNPs with effect 
direction inconsistent with GIANT-BMI results are highlighted in red. 
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Table 3. Association results with FTO SNP rs9939609 and NEGR1 SNP 
rs2815752 in categories of BMI, compared with normal-weight controls 
 
 
 
 
 
 
 
 
 
 BMI Category (kg/m²) 
 
 35.0-
39.9 
40.0-
44.9 
45.0-
49.9 
50.0-
59.9 
≥60.0 
FTO SNP 
rs9939609 
     
n 116 237 270 246 84 
P   0.1 0.01 0.002 0.047 3.4x10-6 
β 0.35 0.35 0.40 0.26 1.08 
SE 0.21 0.14 0.13 0.13 0.23 
      
 
NEGR1 SNP 
rs2815752 
     
n 116 239 266 250 83 
P 0.11 0.01 0.08 0.07 0.93 
β 0.32 0.33 0.22 0.22 0.02 
SE 0.20 0.13 0.12 0.12 0.22 
 
β, effect size; SE, standard error 
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